ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib-Reference-Cited by-同舟云学术

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Published:2019-12 Issue: Volume:138 Page:13-18
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Thunnissen E.,Lissenberg-Witte B.I.,van den Heuvel M.M.,Monkhorst K.,Skov B.G.,Sørensen J.B.,Mellemgaard A.,Dingemans A.M.C.,Speel E.J.M.,de Langen A.J.,Hashemi S.M.S.,Bahce I.,van der Drift M.A.,Looijen-Salamon M.G.,Gosney J.,Postmus P.E.,Samii S.M.S.,Duplaquet F,Weynand B.,Durando X.,Penault-Llorca F.,Finn S.,Grady A.O,Oz B.,Akyurek N.,Buettner R.,Wolf J.,Bubendorf L.,Duin S.,Marondel I.,Heukamp L.C.,Timens W.,Schuuring E.M.D.,Pauwels P.,Smit E.F.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference44 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in alk-mutation-positive non–small-cell lung cancer;Solomon;J. Clin. Oncol.,2018

3. Molecular testing guideline for selection of lung Cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular patho;Lindeman;J. Mol. Diagn.,2013

4. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Novello;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2016

5. Immunohistochemistry of pulmonary biomarkers: a perspective from members of the pulmonary pathology society;Thunnissen;Arch. Pathol. Lab. Med.,2018

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discordant ALK Status in Non-Small Cell Lung Carcinoma: A Detailed Reevaluation Comparing IHC, FISH, and NGS Analyses;International Journal of Molecular Sciences;2024-07-26

2. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

3. Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer;The Journal of Pathology: Clinical Research;2022-07-18

4. ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing;JTO Clinical and Research Reports;2021-10

5. Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru;The Journal of Molecular Diagnostics;2021-09